MannKind Corporation (NASDAQ:MNKD) moves a step ahead in getting its first product marketed as the drugmaker’s inhaled diabetes treatment wins the support of a U.S. advisory panel.MannKind Corporation (NASDAQ:MNKD) stock opened today at $7.19 and is currently trading at $6.82. The stock showed a positive weekly performance of 29.93%.
The Shareholders Foundation announces that an investigation on behalf of current long-term investors in shares of Galena Biopharma Inc (NASDAQ:GALE) was initiated concerning whether certain Galena Biopharma directors and officers breached their fiduciary duties and caused damages to the company and NASDAQ:GALE stockholders.Galena Biopharma Inc (NASDAQ:GALE) stock opened at $2.50, in current trading session and currently is at $2.38, by loosing -3.06%. The 52 week range of $1.65-$7.77. Company’s market capitalization is $279.37 million.
The Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Apr. 1 announced the appointment of E.J. Brandreth as Vice President of Quality. He will be responsible for all quality and compliance functions for a company that is moving forward with numerous late and early stage clinical trials and scaling up manufacturing and other operational areas to support its broad pipeline of immunotherapies and DNA vaccines. He will report to Inovio’s Chief Operating Officer Dr. Niranjan Sardesai. Prior to joining Inovio, Mr. Brandreth had a successful career transitioning start-up clinical biotech operations into successful commercial entities; he supported the growth of several pharmaceutical companies in the quality and compliance areas.Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock is currently trading at $3.39 .The EPS of the stock is -0.35. Company’s market capitalization is $812.28 million.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) reported in previous week, that it had initiated phase 1 testing of its drug candidate RX3117 which has been designed to treat cancer. The clinical test’s end points gaols include the gathering of pharmacokinetic data to draw a profile of the target drug, while establishing the effectiveness of the drug against cancer. The enrollment of patients for this early stage testing has begun and is expected to be completed by end of Fy14.Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock opened the session at $1.28, and now is at $1.21. The 52 week range of the RNN stock remained $0.28-$1.85 and the day range was $1.21-$1.29.
Leave a Reply